Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

@article{Iversen2006Bicalutamide1M,
  title={Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years},
  author={Peter Iversen and Jan-Erik Johansson and P{\"a}r Lodding and Timo Kylm{\"a}l{\"a} and Per I. Lundmo and Peter Klarskov and Teuvo L.J. Tammela and Ilker Tasdemir and Thomas W. Morris and Jon M Armstrong},
  journal={Scandinavian Journal of Urology and Nephrology},
  year={2006},
  volume={40},
  pages={441 - 452}
}
Objective. The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1–2, N0/N×) or locally advanced (T3–4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC… Expand
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy,Expand
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
TLDR
The addition of early bicalutamide to standard of care resulted in a significant OS benefit in patients with locally advanced PCa, and patients with localised PCa and low PSA derived no survival benefit from early bICALutamide. Expand
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
TLDR
Both therapies were well tolerated with a good QoL, however, despite a trend toward higher efficacy of the combined therapy, progression-free survival and overall survival was not significantly different between the groups. Expand
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
TLDR
In patients with locally advanced or high-risk local prostate cancer, addition of local radiotherapy to endocrine treatment halved the 10-year prostate-cancer-specific mortality, and substantially decreased overall mortality with fully acceptable risk of side-effects compared with endocrine Treatment alone. Expand
The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer
TLDR
In patients receiving radiotherapy for locally advanced disease, bicalutamide 150 mg significantly reduced the risk of death by 35%; the magnitude of this benefit compares favorably with that of adjuvant luteinizing hormone-releasing hormone agonist therapy in a similar population. Expand
Re: Endocrine Treatment, with or without Radiotherapy, in Locally Advanced Prostate Cancer (SPCG-7/SFUO-3): An Open Randomised Phase III Trial
TLDR
This randomised trial included men from 47 centres in Norway, Sweden, and Denmark with locally advanced prostate cancer and the primary endpoint was prostate-cancer-specifi c survival. Expand
Update on the management of prostate cancer with goserelin acetate: patient perspectives
TLDR
The current recommendations for androgen deprivation therapy are reviewed and the reasons for these changes are documents, in a review of the world’s literature on ADT over the last 5 years. Expand
Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer
TLDR
Bicalutamide as adjuvant therapy or monotherapy should be considered as an alternative to other available hormonal therapies in men with locally advanced prostate cancer, especially in those who wish to maintain an active lifestyle. Expand
Radical prostatectomy versus watchful waiting for prostate cancer.
TLDR
The existing trials provide insufficient evidence to allow confident statements to be made about the relative beneficial and harmful effects of RP and WW for patients with localised prostate cancer, and the results of ongoing trials should help to inform treatment decisions for men with screen-detected localisation prostate cancer. Expand
Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer.
  • B. Jereczek-Fossa, R. Orecchia
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2007
TLDR
The standard treatment options based on the risk category (stage, Gleason score, PSA) for localized prostate cancer include surgery, radiotherapy and watchful waiting, whereas both approaches differ in their side effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
TLDR
It is confirmed that bicalutamide provides benefit in patients with locally advanced disease and early or adjuvant hormonal therapy for patients at low risk of disease progression, such as those with localized disease, is not appropriate. Expand
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
TLDR
Bicalutamide (150 mg) provides significant benefit in patients with locally advanced prostate cancer, and in previously untreated patients there may be a tumor burden below which endocrine therapy provides no benefit or may even decrease survival. Expand
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
TLDR
Bicalutamide 150 mg as immediate therapy, either alone or as adjuvant to treatment of curative intent, significantly reduces the risk of disease progression in patients with early prostate cancer. Expand
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
TLDR
Bicalutamide 150 mg daily as immediate therapy, alone or as adjuvant to treatment of curative intent, significantly reduced the risk of disease progression in patients with localized or locally advanced prostate cancer. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
PURPOSE We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locallyExpand
Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.
  • P. Walsh
  • Medicine
  • The Journal of urology
  • 2005
TLDR
The natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy is found to be weak. Expand
Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
TLDR
Therapeutic radiotherapy, using two fractions of 6 Gy external-beam radiation to the male breast, improves the intensity of bicalutamide-induced gynaecomastia and/or breast pain in approximately one-third of patients. Expand
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
TLDR
Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated and tamoxifen has been shown to be more effective and safe than RT in this setting. Expand
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.
TLDR
The results consistently favour immediate treatment, although some of the data, especially on MO patients, are immature. Expand
...
1
2
3
...